Inovio Pharmaceuticals, Inc. (LON:0A43)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 63.97M |
| Revenue (ttm) | 151.77K |
| Net Income (ttm) | -84.22M |
| Shares Out | n/a |
| EPS (ttm) | -3.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,070 |
| Average Volume | 14,389 |
| Open | 2.160 |
| Previous Close | 2.190 |
| Day's Range | 2.150 - 2.300 |
| 52-Week Range | 1.418 - 11.804 |
| Beta | n/a |
| RSI | 57.75 |
| Earnings Date | Feb 28, 2025 |
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi... [Read more]
Financial Performance
In 2023, Inovio Pharmaceuticals's revenue was $832,010, a decrease of -91.89% compared to the previous year's $10.26 million. Losses were -$135.12 million, -51.71% less than in 2022.
Financial numbers in USD Financial StatementsNews
Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)
Inovio respiratory DNA drug candidate shows promise in early trial
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEE...
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa. , Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:I...
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PLYMOUTH MEETING, Pa. , Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
PLYMOUTH MEETING, Pa. , Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher by 17.9% to $2.27 Tuesday afternoon amid growing concerns about respiratory illnesses , including seasonal influenza, COVID-19 and R...
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Inovio Pharmaceuticals: The Dangerous Allure Of A Falling Knife
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday. The Dow traded down 0.14% to 43,851.19 while the NASDAQ rose 0.04% to 19,911.75. The S&P 500 also fell, dro...
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday.
Why Inovio Pharmaceuticals (INO) Stock Is Down 40%
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading lower by 40% to $2.23 during Friday’s session after the company priced a public offering of 10 million shares of common stock and accompany...
INOVIO stock slides after pricing $30M equity offering
INOVIO Pharmaceuticals (NASDAQ:INO) shares plunged 21% premarket on Friday after the biotech firm priced an offering to raise $30M in proceeds.The offering...
INOVIO Announces Pricing of $30 Million Public Offering
PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot...
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot...
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients w...
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - ...
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell respons...
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tis...
INOVIO to Present at Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response ag...
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...